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SUMMARY Aims: Limited information is available on the source of medications taken 
in intentional drug overdoses (IDOs). The present study aimed to investigate the proportion 
of patients who engaged in IDOs with current prescriptions and the proportion of those 
that used their medicines in overdose acts, as well as the factors associated with patients 
who do so. Methods: The registration systems of three hospital emergency departments 
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Psychotropic medication involved 
in intentional drug overdose: 
implications for treatment
Practice points
  Patients who engage in intentional drug overdose are more likely to be depressed and to have previously 
engaged in self-harm compared with other self-harm patients who have not engaged in intentional drug 
overdose.
  While psychotropic drugs have an established efficacy in treating psychiatric conditions, there is evidence of a 
link between increased prescribing rates and increased use in intentional drug overdose.
  Having a prescription of a minor tranquilizer increases the risk of using prescribed psychotropic drugs in 
intentional overdoses that are independent of other studied risk factors.
  Among intentional drug overdose patients with a history of previous self-harm, a high proportion were in 
contact with psychiatric services, which underlines the need for careful monitoring of medication in this 
setting.
  The risk of taking one’s own prescription medication in intentional overdoses increases with age and an 
increased number of prescription medications, including minor tranquilizers, which implies that minor 
tranquilizers should be prescribed with caution in older people.
  Consideration should be given to complementary therapies for patients with anxiety disorders, such as 
cognitive–behavioral therapy.
  Differences between countries with regard to the frequency of psychotropic drugs used in intentional 
overdoses are likely to reflect differences in prescribing practice and access to these drugs via illegal sources.
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participating in the Irish National Registry of Deliberate Self Harm were screened over a 
continuous 6-month period and a consecutive series of 299  IDO presentations were 
identified. Results: Most of the IDO presentations involved female patients (59.9%) and 
half (50.4%) had a previous history of self-harm. The prescription of psychotropic drugs 
was associated with the use of these drugs in IDOs, particularly minor tranquilizers. Having 
a prescription of a minor tranquilizer increased the risk of using prescribed psychotropic 
drugs in IDOs even when controlling for other factors. Conclusion: These findings highlight 
the importance of considering the risk of IDO among patients who are prescribed minor 
tranquilizers.
Suicidal behavior is a significant health prob-
lem and has a strong association with psychiatric 
disorders such as mood and anxiety disorders 
[1,2]. Intentional drug overdose (IDO) is the 
most common form of hospital-treated delib-
erate self-harm [3,4]. In general, psychotropic 
drugs, such as minor and major tranquilizers, 
selective serotonin reuptake inhibitors (SSRIs) 
and barbiturates are over-represented in IDOs 
[5–7], accounting for up to 80% of IDOs involv-
ing prescription drugs [8]. In Ireland, approxi-
mately 68% of all hospital-treated episodes of 
deliberate self-harm involve an IDO [3], and, 
of these, minor tranquilizers (benzodiazepines) 
are present in approximately 43% of cases [9]. 
This percentage is three-times that recorded in 
England [4], suggesting a particularly high risk 
for self-harm associated with this medication in 
Ireland and reflecting differences between the 
countries in terms of prescribing patterns and 
other sources of access to benzodiazepines.
Few studies, particularly in recent years, have 
focused on the source of medications taken in 
IDO acts. It has been consistently indicated that 
overdose patients primarily take their own medi-
cation in IDOs [5,10,11]. In addition, individu-
als who engage in IDOs are more likely to be 
depressed and to have previously engaged in self-
harm compared with other self-harm patients 
who do not engage in IDOs [1,10,12]. While not 
all studies distinguish between types of pre-
scribed medication in cases of IDO, factors such 
as single and multiple psychotropic drug use and 
repeat prescribing are identified as being strongly 
associated with repeat overdoses [12]. While psy-
chotropic drugs have an established efficacy in 
treating psychiatric conditions, there is evidence 
of a link between increased prescribing rates and 
increased use in IDOs [13].
Restricting access to means has been shown 
to be one of the most effective strategies in 
both self-harm and suicide prevention [14]. In 
Ireland, in 2006, the withdrawal of Distalgesic 
(a prescription-only compound of paracetamol) 
resulted in an 84% reduction in the rate of IDO 
presentations to hospital emergency departments 
(EDs) involving Distalgesic compared with the 
previous 3 years before it was withdrawn [15], 
without a significant substitution effect. Similar 
findings were observed in England and Wales 
in the 6 years following the withdrawal of co-
proxamol from the market [16]. Based on a com-
parative study including data on intentional 
paracetamol overdoses in the UK and Ireland, 
an association was found between paracetamol 
pack sizes and the number of tablets involved in 
overdoses [17]. 
Knowing the extent to which patients who 
present to hospital EDs as a result of IDO have 
taken their prescribed medications in the act 
should inform preventive initiatives. If this is 
rare, then the focus should be placed on the avail-
ability of over-the-counter medicines, however, if 
this is common, then the revision of prescribing 
practices and other measures aimed at reducing 
access to relevant prescribed medications should 
be considered. Within this context, the present 
study aims to investigate the proportion of IDO 
patients with current prescriptions and the pro-
portion of those that used their medicines in 
overdose acts, as well as factors associated with 
these patients.
Methods
 Setting
The National Registry of Deliberate Self Harm 
records deliberate self-harm presentations to all 
hospital EDs in Ireland with ethical approval 
granted by the National Research Ethics Com-
mittee of the Faculty of Public Health Medicine 
[3]. For the purposes of this study, additional 
data to that routinely recorded were obtained 
from three hospital EDs in the southeast of 
Ireland. These hospitals were selected follow-
ing an assessment of the completeness of data 
available in Irish hospital EDs, which found 
that the information required for the study was 
routinely recorded in these hospitals for the vast 
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majority of IDO presentations. The three study 
hospitals also had adjacent catchment areas, 
which together had a catchment population of 
383,738 individuals, which is 8.5% of the total 
Irish population. It was also established that it 
was rare for study catchment area residents who 
had an IDO to present to a hospital other than 
the three selected.
 Data collection
The registration systems of the three hospital 
EDs studied were screened over a continuous 
6-month period and a consecutive series of 
345 presentations were identified as meeting 
the definition of deliberate self-harm used by 
the Registry: “an act with a nonfatal outcome 
in which an individual deliberately initiates 
nonhabitual behavior, that without intervention 
from others will cause self-harm, or deliberately 
ingests a substance in excess of the prescribed 
or generally recognized therapeutic dosage, 
and which is aimed at realizing changes that 
the person desires via the actual or expected 
physical consequences” [18]. This definition was 
derived for an earlier European study and it is 
consistent with that used in the UK multicenter 
study [4]. This definition includes acts involv-
ing varying levels of suicidal intent and various 
underlying motives, such as loss of control, a 
cry for help or self-punishment. The defini-
tion also explicitly clarifies the definition of an 
IDO. Of the 345 self-harm presentations, there 
were 299 IDOs and information as to whether 
the patient had a prescription for psychotropic 
medication was available for 288 of these pre-
sentations. All data were extracted from charts 
in the EDs and medical records of the general 
hospitals. 
 Data analysis
c2 tests were used to assess the associations 
between two categorical variables. c2 tests for a 
trend were reported when one of the categorical 
variables was ordinal (e.g., age group) and there 
was evidence of a linear pattern in the associa-
tion. A series of simple logistic regression models 
were estimated, including data only from those 
with current prescriptions (active at the time 
of presentation). The dichotomous dependent 
variable was medication taken from current pre-
scription in the IDO act. Factors for which their 
association with the dependent variable reached 
(p < 0.05) or approached (p < 0.1) statistical 
significance were then entered together into a 
multivariate logistic regression model to identify 
the factors independently associated with tak-
ing one’s own currently prescribed medication 
in IDO. This approach was adopted because 
the sample size was relatively limited and there 
was a degree of multicollinearity between some 
of the independent variables. Odds ratios and 
their 95% CIs are reported with the associated 
level of statistical significance. SPSS® Statistics 
Version (IBM, NY, USA) 20 was used for the 
statistical analysis. 
Results
Most of the 288 IDO presentations involved 
female patients (59.9%) and half (50.4%) had 
a previous history of self-harm (Table 1). Other 
methods of self-harm were rarely involved. Self-
cutting had taken place in 16 (5.6%) cases. 
Approximately two-thirds (68.4%) of the 
288 IDO presentations were currently prescribed 
medication and 58.0% had a current prescrip-
tion for psychotropic medication. More than 
half (53.8%) had used alcohol in combination 
with the overdose.
 Drugs taken in IDO
The types of drugs taken in the 288 IDO pre-
sentations are detailed in Table 2. Almost half 
(45.8%) involved a minor tranquilizer and one 
in four (24.7%) involved a paracetamol-only 
medication. 
As can be seen from Figure  1, there were 
clear differences in the drugs taken in IDOs by 
patients currently prescribed with psychotropic 
medication and other patients. Psychotropic 
medications were far more likely to be involved 
in patients with prescriptions for these drugs, 
whereas analgesics, most of which would be 
available over the counter, were more common in 
patients without a prescription for psycho tropic 
medication. For all but three drugs (salicylate 
compound, opiate and tricyclic antidepressants) 
the level of significance was p < 0.05. There was 
only one gender difference in the drugs involved 
in IDO. One in five (20.5%) male IDOs involved 
a major tranquilizer, compared with just 5.8% of 
female acts (c2[1]: 14.35; p < 0.001).
 Contact with psychiatric services
Overall, one in three IDO patients was known 
to be in contact with psychiatric services at the 
time of the act. These patients were generally 
older (c2 for trend[1]: 26.14; p < 0.001; 37.9 
vs 16.1% over 45 years), more likely to have 
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a medical card entitling them to free medical 
care owing to their economic circumstances 
(c2[1]: 16.19; p < 0.001; 69.5 vs 44.3%) and 
more likely to have a history of self-harm 
(c2[1]: 25.24; p < 0.001; 71.3 vs 39.5%) than 
those not in contact with psychiatric services. 
All patients with psychiatric contact had a 
current prescription that compared with just 
over half (52.4%) of the other IDO patients 
(c2[1]: 65.48; p < 0.001) and they were pre-
scribed more medications (c2 for trend[1]: 
117.56; p < 0.001; 52.6% prescribed four to six 
medicines vs 5.7%).
 Prescription medication
As can be seen in Table 3, the 196 IDO patients 
with a current prescription for a known medica-
tion were generally older (24.0% under 30 years 
vs 70.3%; c2 for trend[1]: 54.18; p < 0.001), more 
likely to have a medical card (64.8 vs 26.7%; 
c2[1]: 35.98; p < 0.001), to have a history of self-
harm (58.6 vs 32.2%; c2[1]: 16.73; p < 0.001) 
and to be in current contact with psychiatric 
services (48.5 vs 0%; c2[1]: 65.93; p < 0.001). 
The vast majority had psychotropic medication 
on their current prescription (85.2%) and this 
most often involved a minor tranquilizer.
More than half (95; 56.9%) of the 167 patients 
with a prescription for psychotropic medication 
were in current contact with psychiatric services, 
although this varied depending on the prescribed 
drug: major tranquilizer, 90.7%; barbiturate, 
72.4%; other antidepressant/mood stabilizer, 
72.1%; SSRI, 61.4%; and minor tranquilizer, 
61.4%. It also varied depending on the number 
of prescribed psychotropic drugs. Respectively, 
31.3, 62.9, 89.3 and 100% of patients prescribed 
one, two, three or four psychotropic drugs were 
current psychiatric patients.
 Factors associated with taking one’s own 
prescribed medication in IDOs
In total, 82.1% of those with a current pre-
scription took medication from their prescrip-
tion in the IDO act. From the univariate ana-
lysis, taking one’s own prescribed medication 
in IDO was more common in men, although 
this narrowly failed to reach statistical signifi-
cance (p = 0.055). It was found to be more com-
mon with increasing patient age, with increas-
ing number of prescribed medications and if a 
minor tranquilizer was one of the prescribed 
drugs (Table 4). Multivariate logistic regression 
indicated that having a prescription for minor 
tranquilizers was the only factor independently 
associated with a patient taking an IDO of their 
own medication (odds ratio: 4.27; p < 0.01; 
95% CI: 1.49–12.25). 
Table 1. Characteristics of intentional drug overdose presentations.
Characteristic Patients; n (%)
Gender
Male 117 (40.6)
Female 171 (59.4)
Age (years)
<30 111 (38.5)
30–44 110 (38.2)
≥45 67 (23.3)
Medical card†
Yes 151 (52.6)
No 136 (47.4)
History of self-harm‡
Yes 140 (50.2)
No 139 (49.8)
Currently prescribed medication
Yes 197§ (68.4)
No 91 (31.6)
Currently prescribed psychotropic medication
Yes 167 (58.0)
No 121 (42.0)
Contact with psychiatric services
Yes 95 (33.0)
No 193 (67.0)
Presentation day
Weekday 199 (69.1)
Weekend 89 (30.9)
Presentation time†
8 am–12 pm 17 (5.9)
12 pm–4 pm 45 (15.7)
4 pm–8 pm 51 (17.8)
8 pm–12 am 74 (25.8)
12am–4 am 71 (24.7)
4 am–8 am 29 (10.1)
Brought by ambulance¶
Yes 153 (53.7)
No 132 (46.3)
Alcohol taken
Yes 155 (53.8)
No 133 (46.2)
Admitted to hospital
Yes 266 (92.4)
No 22 (7.6)
†Data not known for one case. 
‡Data not known for nine cases. 
§Prescribed drugs unknown for one case. 
¶Data not known for three cases.
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Discussion
The present study showed an association 
between prescription of psychotropic drugs and 
the use of these drugs in IDOs, in particular 
minor tranquilizers, SSRIs and major tran-
quilizers. Although limited research has been 
conducted in this area, the findings of the cur-
rent study are consistent with previous studies 
[5,8,12,19]. However, the present study identified 
that having a prescription of a minor tranquil-
izer increases the risk of using prescribed psy-
chotropic drugs in IDOs independent of any 
other studied risk factor. In their study of IDOs 
involving psychotropic drugs, Tournier et al. 
found that the proportion of IDOs involving 
a benzodiazepine was the same whether the 
patient had taken at least one of his/her own 
prescribed psycho tropic drugs (79.0%) or not 
(81.6%) [5]. They suggested that their findings 
were consistent with those of an earlier Spanish 
study [19], which indicated that benzodiazepine 
overdose was independent of the individual’s 
prescription [5]. This indicates the existence 
of differences between countries that may be 
related to prescribing practices, accessibility and 
availability of alternative interventions.
In our study, just under two thirds of IDO 
patients using minor tranquilizers were in con-
tact with the psychiatric services at the time 
of the IDO. This suggests a high incidence of 
psychiatric disorders in this group. Given that 
psychiatric disorders are a significant risk fac-
tor for suicidal behavior, the findings highlight 
the challenge of prescribing medication for the 
treatment of the patient’s psychiatric disorder 
while assessing their risk for IDO.
The findings have implications for the pre-
scription of psychotropic medication to patients 
at risk of suicidal behavior. More care and 
restraint in prescribing practices, and investiga-
tion into illegal sources in order to reduce the 
incidence of overdose would be recommended. 
A review by Smith and Tett demonstrated that 
studies using a multifaceted approach had the 
largest and most sustained reductions in the 
use of minor tranquilizers [20]. Elements con-
sidered to enhance the success of interventions 
include advice to patients to reduce or stop the 
use of minor tranquilizers, encourage an inter-
professional approach, such as pharmacists 
alerting prescribers of potentially inappropriate 
prescribing of minor tranquilizers, and educa-
tion of staff about alternative methods to treat 
insomnia and reduce anxiety [20]. In considering 
alternative drugs to minor tranquilizers, there is 
a need to be concerned about prescribing more 
toxic drugs as these may be used in IDOs, result-
ing in more severe consequences for the patient. 
Hawton and Harriss reported a decreasing trend 
in IDOs involving tranquilizers and sedatives, 
and an increase in antidepressant overdoses 
between 1978 and 1997, reflecting changes in 
prescribing patterns [21].
The significantly higher proportion of IDO 
patients with a history of previous self-harm 
among those who were in contact with psy-
chiatric services at the time of the index IDO 
underlines the need for careful monitoring of 
Table 2. Type of drug used in intentional drug overdose by gender.
Drug type Male (n = 117); % Female (n = 171); % Total (n = 288); %
Salicylate 5.1 5.3 5.2
Salicylate compound 6.0 2.9 4.2
Paracetamol 18.8 28.7 24.7
Paracetamol compound 13.7 10.5 11.8
Opiate 4.3 6.4 5.6
Opiate compound 12.8 10.5 11.5
Minor tranquilizer 47.0 45.0 45.8
NSAIDs/other analgesic 13.7 16.4 15.3
Major tranquilizer 20.5 5.8 11.8
SSRI 12.8 16.4 14.9
TCAD 0.0 2.3 1.4
Other antidepressant/mood stabilizers 6.0 7.6 6.9
Antiepileptic/barbiturate 7.7 7.0 7.3
Other 20.5 18.7 19.4
Street drug 5.1 8.2 6.9
SSRI: Selective serotonin reuptake inhibitor; TCAD: Tricyclic antidepressant.
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the use of medication among this subgroup of 
IDO patients. Consideration should also be 
given to the provision of complementary thera-
pies, such as cognitive–behavioral therapy [14,22]. 
Based on a review by Otte, cognitive–behavioral 
therapy demonstrates both efficacy in random-
ized controlled trials and effectiveness in natu-
ralistic settings in the treatment of adult anxiety 
disorders [23].
The risk of taking one’s own prescribed medi-
cation in IDOs increased with age, an increas-
ing number of prescription medications and if a 
minor tranquilizer was one of the medications 
prescribed. These findings are in line with a 
Swedish study, in which the use of minor tran-
quilizers was common in drug poisoning suicides 
among older people in which the terminal cause 
of death was often drowning [24]. This implies 
that minor tranquilizers should be prescribed 
with caution for this age group.
 Strengths & limitations
The study sample size was limited, although it 
had the merit of being drawn from a consecutive 
series of presentations to three hospital EDs oper-
ating in a geographically defined catchment area, 
thereby minimizing a range of potential biases. 
The data were extracted from hospital records 
and notes by Heavey who operated according to 
standard operating procedures and showed very 
high levels of agreement (k > 0.9) with colleagues 
in case ascertainment. The study was constrained 
by the availability of information in hospital 
records and the reliability of the information 
obtained could not be established. Specifically, 
information was lacking regarding psychiatric 
Prescribed psychotropic medication
Not prescribed psychotropic medication
Street drug
0 10 20
IDO presentations (%)
30 40 50 60 70
Other
Antiepileptic/barbiturate
Other antidepressant/
mood stabilizer
TCAD
SSRI
Major tranquilizer
Minor tranquilizer
NSAIDs/other analgesic
Opiate compound
Opiate
Paracetamol compound
Paracetamol
Salicylate compound
Salicylate
Figure 1. Type of drug used in intentional drug overdose for those prescribed and not prescribed 
psychotropic medication. 
IDO: Intentional drug overdose; SSRI: Selective serotonin reuptake inhibitor; TCAD: Tricyclic 
antidepressant.
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diagnosis, and the nature and duration of con-
tact with psychiatric services and, in a minority 
of cases, generic drug names or drug types were 
specified instead of proprietary drug names.
The present study obtained data from the hos-
pital ED setting on a consecutive series of IDO 
patients, which meant that it was not possible 
to examine the risk of taking an IDO among 
patients with current prescriptions for a range 
of psychotropic medications. There is a need 
for studies to address this, and such studies will 
need to be based on patients in the primary care 
Table 3. Characteristics of intentional drug overdose presentations by individuals with and 
without current prescriptions.
Characteristic Current prescription
Yes (n = 196)†; n (%) No (n = 91); n (%)
Gender
Male 85 (43.4) 31 (34.1)
Female 111 (56.6) 60 (65.9)
Age (years)
30 47 (24.0) 64 (70.3)
30–44 88 (44.9) 22 (24.2)
≥45 61 (31.1) 5 (5.5)
Medical card‡
Yes 127 (64.8) 24 (26.7)
No 69 (35.2) 66 (73.3)
History of self-harm§
Yes 112 (58.6) 28 (32.2)
No 79 (41.4) 59 (67.8)
Alcohol taken
Yes 111 (56.6) 44 (48.4)
No 85 (43.4) 47 (51.6)
Contact with psychiatric services
Yes 95 (48.5) 0 (0)
No 101 (51.5) 91 (100)
Prescribed medications (n)
1 50 (25.5) –
2 55 (28.1) –
3 30 (15.3) –
4–6 61 (31.1) –
Psychotropic medication prescribed
Yes 167 (85.2) –
No 29 (14.8) –
Type of psychotropic medication prescribed
Minor tranquilizer 127 (64.8) –
Major tranquilizer 43 (21.9) –
SSRI 70 (35.7) –
Tricyclic AD 3 (1.5) –
Other AD/mood stabilizer 43 (21.9) –
Barbiturate 29 (14.8) –
Took own prescribed medication in IDO
Yes 161 (82.1) –
No 35 (17.9) –
†Excludes one patient whose prescribed medication was unknown. 
‡Not know for one case. 
§Not know for nine cases. 
AD: Antidepressant; IDO: Intentional drug overdose; SSRI: Selective serotonin reuptake inhibitor.
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setting or psychiatric outpatients. Longitudinal 
studies from these settings would make it pos-
sible to disentangle the links between depression, 
prescription of antidepressants and engaging in 
suicidal behavior.
Conclusion
Prescription of psychotropic drugs was associated 
with the use of these drugs in IDOs, in particu-
lar minor tranquilizers. Having a prescription of 
a minor tranquilizer increased the risk of using 
Table 4. Factors associated with taking own prescribed medication in intentional drug overdose.
Characteristic Took own 
medication; 
n (%)
Crude OR 95% Cl Adjusted OR 95% Cl
Gender
Male 75 (88.2) 2.18 0.98–4.83 2.30 0.97–5.46
Female 86 (77.5) 1.00 Ref 1.00 Ref
Age (years)
<30 32 (68.1) 1.00 Ref 1.00 Ref
30–44 75 (85.2) 2.70* 1.16–6.33 1.53 0.58–4.07
≥45 54 (88.5) 3.62* 1.33–9.81 1.58 0.49–5.04
Medical card
Yes 107 (84.3) 1.49 0.71–3.13 – –
No 54 (78.3) 1.00 Ref – –
History of self-harm
Yes 93 (83.0) 1.15 0.54–2.42 – –
No 64 (81.0) 1.00 Ref – –
Alcohol taken
Yes 93 (83.8) 1.29 0.62–2.69 – –
No 68 (80.0) 1.00 Ref – –
Contact with psychiatric services
Yes 82 (86.3) 1.76 0.83–3.73 – –
No 79 (78.2) 1.00 Ref – –
Prescribed medications (n)
1 34 (68.0) 1.00 Ref 1.00 Ref
2 44 (80.0) 1.88 0.77–4.58 0.91 0.32–2.56
3 26 (86.7) 3.06 0.91–10.25 1.21 0.30–4.91
4–6 57 (93.4) 6.71** 2.07–21.72 2.40 0.59–9.71
Minor tranquilizer prescribed
Yes 117 (92.1) 6.65*** 2.95–14.96 4.27** 1.49–12.25
No 44 (63.8) 1.00 Ref 1.00 Ref
Major tranquilizer prescribed
Yes 38 (88.4) 1.85 0.67–5.11 – –
No 123 (80.4) 1.00 Ref – –
SSRI prescribed
Yes 61 (87.1) 1.76 0.77–4.01 – –
No 100 (79.4) 1.00 Ref – –
Other AD/mood stabilizer prescribed
Yes 34 (79.1) 0.77 0.33–1.80 – –
No 127 (83.0) 1.00 Ref – –
Barbiturate prescribed
Yes 27 (93.1) 3.33 0.75–14.69 – –
No 134 (80.2) 1.00 Ref – –
*p < 0.05; **p < 0.01; ***p < 0.001. 
AD: Antidepressant; OR: Odds ratio; Ref: Reference group; SSRI: Selective serotonin reuptake inhibitor.
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prescribed psychotropic drugs in IDOs indepen-
dent of any other factor. The risk of taking one’s 
own prescribed medication in IDOs increased 
with age, an increasing number of prescription 
medications and if a minor tranquilizer was one 
of the medications. The findings underline the 
need for more care and restraint in prescribing 
practice, as well as addressing illegal sources in 
order to reduce the incidence of IDOs. 
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